Original Research Paper

**In silico Assessment of the Arg85Trp Glucokinase Mutation Effects**

1,2Faiza Bouldjennet, 1Souhila Bouaziz-Terrachet, 3Malha Azzouz and 2Rachida Raache

1Faculty of Sciences, University M’Hamed Bougara of Boumerdes, Algeria
2Laboratory of Cellular and Molecular Biology, Faculty of Biological Sciences, University of Sciences and Technology Houari Boumediene, Algiers, Algeria
3Department of Diabetology, Mustapha Pacha Hospital, Algiers, Algeria

**Abstract:** Maturity Onset Diabetes of the Young (MODY) is a heterogeneous group of autosomal dominantly inherited, young-onset β-cell disorders that account for approximately 2% of non-insulin-dependent diabetics in Europe. MODY2 or GCK-MODY is caused by inactivating heterozygous mutations in the glucokinase. Linkage of MODY to the Arg85Trp GCK mutation, among Algerian diabetic patients has been established in our previous research. The main objective of this study is to strengthen the evidence for the pathogenicity of this mutation using bioinformatics tools. For this purpose, prediction of Arg85Trp mutation effect on glucokinase (PDB ID: 1V4T) stability was performed using I-Mutant 3.0, PoPMuSiC 3.1, DUET and mCSM web servers. Otherwise, structural analysis was performed after optimization of the native and the mutated structures (PDB ID: 1V4T). For that the steepest descent geometries optimization were applied using Nano Molecular Dynamics software (NAMD 2.12). Subsequently, interactions established between the native Arg85 or the mutated Trp85 and the surrounding residues were studied using Accelrys Discovery Studio Visualizer software. *In silico* analysis conducted through I-Mutant 3.0, PoPMuSiC 3.1, DUET and mCSM softwares, predicts the Arg85Trp as a destabilizing mutation. Structural modeling gives further evidence in favor of the pathogenicity of this mutation. Overall, our results corroborate with the previous metabolic and *in silico* studies which associate Arg85Trp mutation to MODY phenotype.

**Keywords:** *In silico*, Glucokinase, Arg85Trp Mutation, Stability, Structural Modeling

**Introduction**

Maturity Onset Diabetes of the Young (MODY) is a heterogeneous group of autosomal dominantly inherited, young-onset β-cell disorders that account for approximately 2% of non-insulin-dependent diabetics in Europe. Heterozygous inactivating mutations in the *GCK* gene encoding the glucokinase have been linked to a subtype of Maturity Onset Diabetes of the Young (MODY) named MODY2 or GCK-MODY (OMIM. 125851) (Vionnet et al., 1992). GCK-MODY is the most common form of MODY diabetes in several countries, including Italy (Capuano et al., 2012; Massa et al., 2001), France (Chevre et al., 1998), Spain (Barrio et al., 2002; Estalella et al., 2007) and others.

In our previous investigation (Bouldjennet et al., 2019), we have demonstrated linkage of MODY to the Arg85Trp GCK mutation among Algerian diabetic patients. We have also revealed: (a) The high conservation of the arginine residue at position 85 of the glucokinase; (b) the probable effect of the Arg85Trp mutation on glucokinase structure/function and stability of the glucokinase (PDB: 1V4S) and (c) within the glucokinase, the substitution of the Arg85 by a Trp85 residue led to abolition/creation of interactions with the surrounding residues (Bouldjennet et al., 2019).

In this study we use bioinformatic approaches in order to strengthen the evidence for the pathogenicity of the detected variant. These approaches were performed using the open structure of the glucokinase (PDB: 1V4T).
Materials and Methods

Prediction of the Arg85Trp mutation effect on glucokinase (PDB ID: 1V4T) stability was performed using I-Mutant 3.0 (Capriotti et al., 2005), PoPMuSiC 3.1 [Prediction of Protein Mutant Stability Changes; (Dehouck et al., 2011)], DUET (Pires et al., 2014a) and mCSM [Mutation Cut off Scanning Matrix; (Pires et al., 2014b)] web servers. Otherwise, structural modeling was performed using the X-ray crystallographic structure of glucokinase (PDB ID: 1V4T) determined at resolution of 3.4Å (Kamata et al., 2004). Initially, the water molecules and heteroatoms were removed; polar hydrogens were added. The native structure underwent 10000 steps of steepest-descent energy minimization to remove atomic overlaps or improper geometries, then it was equilibrated for 50000 run in 100 ps using Nano Molecular Dynamics software (NAMD 2.12) (Phillips et al., 2005) with CHARMM 36 force field. After that, the substitution of the arginine at position 85 by a tryptophan residue was introduced into the energy minimized structure using Visual Molecular Dynamics (VMD) (Humphrey et al., 1996) and again energy minimization was carried out.

Analysis and visualization of interactions established between the native Arg85 or the mutated Trp85 and the surrounding amino acids were performed using Accelrys Discovery Studio Visualizer software version 4.1 (http://www.accelrys.com). Lastly, the native and mutated structures were superposed in order to assess likely changes in the three-dimensional (3D) structures.

Results and Discussion

The stability of the mutated glucokinase was predicted to be altered by all the tested web servers (I-Mutant3.0, PoPMuSiC 3.1, DUET and mCSM) which assess the Arg85Trp mutation to be destabilizing (Table 1).

Structural modeling of the native structure revealed that in the open structure of the glucokinase (PDB: 1V4T) the arginine 85 is located in a β sheet (β2 sheet), near a loop structure (Leu79-Asn83) implicated in the active site of the enzyme (Bouldjennet et al., 2019; Petit et al., 2011).

In the native optimized structure, the residue Arg85 is involved in different types of interactions with Asp78 residue: One carbon hydrogen bond, three hydrogen bonds (H bond) and three attractive charge interactions. Furthermore, it establishes two carbon hydrogen bonds with Leu77 and Gln106 and one hydrogen bond with Asn83, (Fig. 1a). These interactions are modified when this small basic arginine residue is substituted by a large hydrophobic tryptophan Trp85. Indeed, in the mutated structure, the new Trp85 residue loses all interactions established between the Arg85 and surrounding residues except three hydrogen bonds with Asp78 residue and the carbon hydrogen bonds with Leu77 and Gln106. Moreover, the three attractive interactions between Arg85 and Asp78 are replaced by π-π stacked interaction with His105 and π-alkyl interaction with Met87 (Fig. 1b).

Fig. 1: View of interactions between; (a) Arg85 in the native structure and surrounding residues; (b) Trp85 in the mutated structure and surrounding residues. Dotted lines correspond to interactions: green to hydrogen bonds, light grey to carbon hydrogen bonds, orange to attractive charge interactions, dark and light pink to π-π stacked and π-alkyl interactions, respectively.
Fig. 2: Superimposition of the native (pink) and mutated glucokinase (bleu). Protein backbones are shown in line ribbon representation.

Table 1: *In silico* predictions of the impact of the Arg85Trp mutation on GCK stability (PDB: 1V4T)

<table>
<thead>
<tr>
<th>Tools predicting mutation effect</th>
<th>I-Mutant v3.0</th>
<th>PoPMuSiC 3.1</th>
<th>DUET</th>
<th>mCSM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect on stability</td>
<td>-0.51</td>
<td>0.07</td>
<td>-0.463</td>
<td>-0.585</td>
</tr>
<tr>
<td>ΔΔG* (Kcal/mol)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*ΔΔG: Gibbs free energy.

These interactions changes within the mutated structure are translated by a change in the 3D structure of the mutated protein compared to the native one (Fig. 2).

We should mention that mutations at the Asp78 which loses some interactions with the Trp85 compared to Arg85 and the Asn83 residue which loses interaction with the Trp85, have been linked to MODY phenotype (Massa et al., 2001; Thomson et al., 2003).

Conclusion

Results of bioinformatic approaches corroborate with the co-segregation of the Arg85Trp glucokinase variant with hyperglycemia. This study supports the deleterious effect of this variation on glucokinase function. However, functional study is needed to highlight altered enzyme’s parameters resulting from the detected mutation.

Author’s Contributions

Faiza Bouldjennet: Designed the study and drafted the manuscript.

Souhila Bouaziz-Terrachet: Performed molecular modeling study, reads and approved the manuscript.

Malha Azzouz: Reads and approved the manuscript.

Rachida Raache (Phd Supervisor): Reads and approved the manuscript.

Ethics

This article is original and contains unpublished material. The corresponding author confirms that all of
the other authors have read and approved the manuscript and no ethical issues involved.

References


